Resultados de procura - Bo Hee Shin
- Mostrando 1 - 6 Resultados de 6
-
1
Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations por Jaebong Jang, Ciric To, Dries J.H. De Clercq, Eunyoung Park, Charles M. Ponthier, Bo Hee Shin, Mierzhati Mushajiang, Radosław P. Nowak, Eric S. Fischer, Michael J. Eck, Pasi A. Jänne, Nathanael S. Gray
Publicado 2020Artigo -
2
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors por Dries J.H. De Clercq, David E. Heppner, Ciric To, Jaebong Jang, Eunyoung Park, Cai‐Hong Yun, Mierzhati Mushajiang, Bo Hee Shin, Thomas W. Gero, David A. Scott, Pasi A. Jänne, Michael J. Eck, Nathanael S. Gray
Publicado 2019Artigo -
3
Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites por Florian Wittlinger, David E. Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K. Rana, Anna M. Schmoker, Tyler S. Beyett, Lena M. Berger, Benedict‐Tilman Berger, Nicolas Bauer, James D. Vasta, Cesear Corona, Matthew B. Robers, Stefan Knapp, Pasi A. Jänne, Michael J. Eck, Stefan Laufer
Publicado 2021Artigo -
4
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor por Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang, Dries J.H. De Clercq, Man Xu, Stephen Wang, Michael D. Cameron, David E. Heppner, Bo Hee Shin, Thomas W. Gero, Annan Yang, Suzanne E. Dahlberg, Kwok‐Kin Wong, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
Publicado 2019Artigo -
5
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer por Ciric To, Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala, Bo Hee Shin, David E. Heppner, Jaimin K. Rana, Brittaney A. Leeper, Kara M. Soroko, Michael J. Poitras, Prafulla C. Gokhale, Yoshihisa Kobayashi, Kamal Wahid, Kari J. Kurppa, Thomas W. Gero, Michael D. Cameron, Atsuko Ogino, Mierzhati Mushajiang, Chunxiao Xu, Yanxi Zhang, David A. Scott, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
Publicado 2022Artigo -
6
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway por Kari J. Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Amir Vajdi, Erik H. Knelson, Yingtian Xie, Klothilda Lim, Paloma Cejas, Andrew Portell, Patrick H. Lizotte, Scott B. Ficarro, Shuai Li, Ting Chen, Heidi M. Haikala, Haiyun Wang, Magda Bahcall, Yang Gao, Sophia Z. Shalhout, Steffen Boettcher, Bo Hee Shin, Tran C. Thai, Margaret K. Wilkens, Michelle Tillgren, Mierzhati Mushajiang, Man Xu, Jihyun Choi, Arrien A. Bertram, Benjamin L. Ebert, Rameen Beroukhim, Pratiti Bandopadhayay, Mark M. Awad, Prafulla C. Gokhale, Paul T. Kirschmeier, Jarrod A. Marto, Fernando D. Camargo, Rizwan Haq, Cloud P. Paweletz, Kwok‐Kin Wong, David A. Barbie, Henry W. Long, Nathanael S. Gray, Pasi A. Jänne
Publicado 2020Artigo
Ferramentas de procura:
Materias Relacionadas
Biology
Allosteric regulation
Cancer research
Gene
Genetics
Mutant
Pharmacology
Receptor
EGFR inhibitors
Epidermal growth factor receptor
Erlotinib
Gefitinib
T790M
Biochemistry
Cancer
Chemistry
Osimertinib
Computational biology
Enzyme
Kinase
Tyrosine kinase
Tyrosine-kinase inhibitor
Apoptosis
Biotechnology
Botany
Cell
Cell biology
Cetuximab
Colorectal cancer
Combination therapy